Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC’s Angelica Peebles and Gilead chairman and CEO Daniel O’Day join 'Squawk Box' to discuss the company's new HIV ...
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...
Gilead reportedly settles CDC patent dispute over HIV drugs
Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...
STAT6h
Biden administration and Gilead settle long-running battle over patents for HIV PrEP pills
After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...
BioSpace2d
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...
Gilead Sciences Inc. stock rises Wednesday, still underperforms market
Shares of Gilead Sciences Inc. GILD rallied 1.52% to $92.38 Wednesday, on what proved to be an all-around great trading ...
Business Wire4d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
'Double moonshot' launch highlights global race to the moon
Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...
Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO Daniel O’Day
Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...
Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.
Christianity Today7d
The Balm of Gilead Grows Again, Maybe
And other news from Christians around the world.
The Marion Star on MSN4d
Cardington pulls away late in its rivalry game with Mount Gilead Saturday afternoon
Cardington overcomes Mount Gilead's second-half rally in a Knox Morrow Athletic Conference boys basketball game.